Skip to main content
. 2020 Jun 25;12(7):415–422. doi: 10.14740/jocmr4227

Table 1. Baseline Characteristics of the Included Population Across Comparison Groups for Which the Pooled Estimate Were Adjusted.

NLR < 10 NLR > 11 Significance LCR < 10 LCR > 11 Significance
Age 63.6 years 61.6 years P = 0.71 62.6 years 63.7 years P = 0.65
Sex
  Men 66 (80.50%) 16 (19.50%) P = 0.167 23 (27.70%) 60 (72.30%) P = 0.04
  Women 75 (88.20%) 10 (11.80%) 13 (14.90%) 74 (85.10%)
DM
  No 92 (85.20%) 16 (14.80%) P = 0.716 23 (21.10%) 86 (78.90%) P = 0.974
  Yes 49 (83.10%) 10 (16.90%) 13 (21.30%) 48 (78.70%)
HTN
  No 48 (80.00%) 12 (20.00%) P = 0.237 14 (23.30%) 46 (76.70%) P = 0.611
  Yes 93 (86.90%) 14 (13.10%) 22 (20.00%) 88 (80.00%)
CAD
  No 114 (82.60%) 24 (17.40%) P = 0.16 30 (21.60%) 109 (78.40%) P = 0.784
  Yes 27 (93.10%) 2 (6.90%) 6 (19.40%) 25 (80.60%)
CKD
  No 114 (83.80%) 22 (16.20%) P = 0.65 28 (20.30%) 110 (79.70%) P = 0.557
  Yes 27 (87.10%) 4 (12.90%) 8 (25.00%) 24 (75.00%)
COPD
  No 119 (83.20%) 24 (16.80%) P = 0.29 32 (21.90%) 114 (78.10%) P = 0.56
  Yes 22 (91.70%) 2 (8.30%) 4 (16.70%) 20 (83.30%)
HCQ
  No 27 (87.10%) 4 (12.90%) P = 0.65 8 (27.60%) 21 (72.40%) P = 0.354
  Yes 114 (83.80%) 22 (16.20%) 28 (19.90%) 113 (80.10%)
TM
  No 117 (84.80%) 21 (15.20%) P = 0.78 28 (20.30%) 110 (79.70%) P = 0.557
  Yes 24 (82.80%) 5 (17.20%) 8 (25.00%) 24 (75.00%)
SD
  No 115 (83.30%) 23 (16.70%) P = 0.39 32 (22.90%) 108 (77.10%) P = 0.247
  Yes 26 (89.70%) 3 (10.30%) 4 (13.30%) 26 (86.70%)
AC
  No 115 (85.80%) 19 (14.20%) P = 0.318 25 (18.40%) 111 (81.60%) P = 0.075
  Yes 26 (78.80%) 7 (21.20%) 11 (32.40%) 23 (67.60%)

DM: diabetes mellitus; HTN: hypertension; CKD: chronic kidney disease; CAD: coronary artery disease; COPD: chronic obstructive pulmonary disease; HCQ: hydroxychloroquine; TM: tocilizumab; SD: steroid; AC: anticoagulation.